NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
PR Newswire•29/10/2026•11:30 ET
3
Key Highlights
- ➤NeuroSense (NRSN) will present PARADIGM findings informing PrimeC’s planned Phase 3 PARAGON study
- ➤FDA cleared NeuroSense to initiate the pivotal PARAGON Phase 3 ALS trial
- ➤JAMA Neurology reported slower functional decline with PrimeC versus initially administered placebo
- ➤PrimeC biomarker changes, including microRNAs, aligned with its proposed multi-target mechanism
Expert Statements
Merit Cudkowicz, Director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at Harvard Medical School
“From PARADIGM to PARAGON: Converging Clinical and Biomarker Findings Informing Phase 3 Development of PrimeC”
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 PR Newswire
Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON
Get started
Create a free account to read the full story.